



## John Ferbas

---

Dr. Ferbas received an M.S. (1989) and Ph.D. (1993) from the University of Pittsburgh School of Public Health and completed a post-doctoral fellowship at the UCLA School of Medicine in 1996. After service to the UCLA School of Medicine and Greater Los Angeles VA Medical Center as an Associate Professor, Dr. Ferbas joined Amgen (1999), where he held positions of increasing responsibility. He currently works in the Department of Medical Sciences the Director of the Cytometry Sciences Group, which represents an integrated core laboratory facility comprised of flow cytometers (analyzers and sorters), single and multiphoton

microscopes and a mass cytometry (CyTOF) platform. Dr. Ferbas oversees a group of approximately 14 scientists at Amgen laboratories located in Thousand Oaks CA, San Francisco CA and Cambridge MA and interacts with hundreds of research scientists across these sites. Dr. Ferbas is a former reviewer for the NIH Small Business Innovation Research / Small Business Technology Transfer Research Study Section and also served as an Editorial Board Member for the Journal of Clinical Vaccine Immunology (Formerly Clinical and Diagnostic Laboratory Immunology). Dr. Ferbas' current interests are centered on high-dimensional, innovative analyses of cell biology as applied to important questions that address discovery, development and commercialization of biologic therapeutics.

Specialties: Cell biology and mechanism of action experiments, Discovery (Research) and Biomarker (Clinical) assay development, Flow and Imaging Cytometry, Mass Cytometry, Immunogenicity assessment, Knowledge of GLP and GCP guidelines



## Paul Hughes

---

Paul Hughes was an undergraduate at the University of Sussex, majoring in Biochemistry. He did his PhD at the University of Oxford followed by post-doctoral research at Scripps Research Institute, La Jolla, California, focused on integrin cell adhesion receptors and signal transduction.

He joined the Oncology Research department at Amgen in 2003, and since that time has progressed several large and small molecule programs from early stages of target identification and validation through pre-clinical proof-of concept and into clinical development.



## Cen Xu

---

Dr Xu is a professionally trained pharmacologist with 30+ years in neuroscience research and 20+ years in neuroscience drug discovery. She is now head of analgesia and migraine research, and a key contributor to Amgen's merging migraine portfolio including AIMOVIG™, AMG 301, and several additional assets that are at different stages of discovery and development.



## Chris Paszty

---

Chris Paszty is a Scientific Director in Cardiometabolic Disorders at Amgen Inc. (Thousand Oaks, CA).

After completing his Ph.D. in plant molecular biology at Washington State University, Chris did postdoctoral work at the Lawrence Berkeley National Laboratory where he developed the widely used "Berkeley" mouse model of sickle cell disease (*Science*, 1997).

He joined Amgen in 1998 and used genomic approaches to discover several new human genes including a novel cystine-knot protein that turned out to be sclerostin.

Since that time he has been the research lead for Amgen's sclerostin program and is the lead author on the team's key preclinical publications demonstrating the bone building potential of antibody-mediated sclerostin inhibition.

The efforts of the research team Chris led has yielded several clinical candidate sclerostin antibodies, including Romosozumab now in Phase 3 trials.